Navigation Links
Data From Anthera's Plasma Trial to be Presented as Late Breaker at American College Of Cardiology Scientific Sessions
Date:2/7/2008

SAN MATEO, Calif., Feb. 7 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that data from the Phase II trial of its novel secretory phospholipaseA2 inhibitor Varespladib (A-002) for the treatment of coronary heart disease will be presented as a late breaker at the 2008 American College of Cardiology 57th Annual Scientific Session on Monday, March 31, 2008 in Chicago, Illinois.

The Phase II trial known as PLASMA (Phospholipase Levels And Serological Markers of Atherosclerosis) was a multi-center, randomized, double-blind, placebo-controlled trial that enrolled approximately 400 patients with stable coronary heart disease in the U.S. and Ukraine. Subjects were randomized to receive one of four different doses of A-002 or placebo for up to eight weeks. Patients also received doctor-determined standard of care therapies. The primary endpoint was a reduction in secretory phospholipase A2 (sPLA2). The study also evaluated the effect of Varespladib on cholesterol levels (LDL-C, non-HDL and total cholesterol) as well as inflammation in patients with stable coronary heart disease.

PLASMA Late-Breaker Trial Data Presentation:

Date/Time: Monday, March 31 from 2:30-2:45pm.

Title/Author: Effects of a Selective Inhibitor of Secretory

Phospholipase A2 on Low Density Lipoproteins and Inflammatory Pathways,

Robert S. Rosenson, MD, Director, Lipoprotein Disorders and Clinical

Atherosclerosis Research, Division of Cardiovascular Medicine at the

University of Michigan, for the PLASMA Investigators.

Location: McCormick Place, Vista Room S406

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a privately-held company committed to developing and commercializing clinical pharmaceutical products that address unmet medical needs of patients with life-threatening, chronic and acute inflammatory diseases and a
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. New Studies Find Plasma Disc Decompression Effective for Contained Disc Herniation
2. PEAK Surgical Announces Positive Surgical Incision Wound Healing Results With the PEAK PlasmaBlade(TM)
3. Test gives insight into prognosis in patients with plasma cell malignancies, finds Mayo Clinic study
4. Study on Plasma-Depleted Cord Blood Transplantation Receives Best Abstract Award From The National Marrow Donor Program
5. Toxoplasma infection increases risk of schizophrenia, study suggests
6. New Heart Pump Shows Promise in Trial
7. Trial to Test Gene Therapy for Angina in Women
8. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
9. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
10. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
11. MDS Pharma Services Wins Award for Management of Global Malaria Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... August 31, 2015 , ... Coast Dental Vista is celebrating its ... a.m. to 3 p.m. near Albertsons in the Foothill Center, located at 1279 E. ... Rivera and Dr. Jay Lopp. Call (760) 208-2518 for more details or stop by ...
(Date:8/31/2015)... ... August 31, 2015 , ... Garden State Urology is ... result of a merger of five of the busiest urology practices in Morris ... more cost-effective and higher quality care than they did individually. Their mission ...
(Date:8/31/2015)... ... August 31, 2015 , ... With the FCPX LUT Soft pack from Pixel Film ... a Lookup Table that contains a mathematical formula for modifying an image. The LUT changes ... 60 soft CUBE LUT files. , FCPX LUT Soft requires Final Cut Pro X ...
(Date:8/31/2015)... , ... August 31, 2015 , ... ... ABBY Awards, at the 16th Innovations in Healthcare(SM) Awards Event , on ... Business Leaders (ABL) Organization , recognizes innovative organizations and individuals who are dramatically ...
(Date:8/31/2015)... ... August 31, 2015 , ... Finnleo , a leader ... Available starting in the 3rd quarter, the newly re-styled and re-designed “Hallmark Series” updates ... tools. , These new models include more glass and a more upscale feel than ...
Breaking Medicine News(10 mins):Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 2Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 3Health News:NJ Top Docs Presents, Garden State Urology! 2Health News:Pixel Film Studios, FCPX Plugin Developer, Releases FCPX LUT Soft 2Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 2Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 3Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 4Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 5Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 6Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 7Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 8Health News:Finnleo Introduces Hallmark Series Saunas 2
... 2 Vista Partners announced,today that it has ... RPTP). "We believe Raptor,s operational approach will serve,as ... as it promotes,operational efficiency, reduced operating costs and ... a Phase II candidate for 2008 in,Convivia(TM), which ...
... 1 Arena Pharmaceuticals, Inc.,(Nasdaq: ARNA ) announced ... of its common stock at a public offering price ... offered by Arena. The underwriters,have a 30-day option to ... to cover over-allotments, if any. CIBC World Markets ...
... Nov. 1 MannKind Corporation,(Nasdaq: MNKD ), focused on ... that it will present at,the following conferences: * The ... Tuesday November 6, 2007 at 2:20 PM ... New York, NY., * The CIBC 18th Annual ...
... 1 Otter Tail,Corporation (Nasdaq: OTTR ) announced financial results ... -- Record third quarter revenues of $302.2 million. -- Consolidated ... compared with $13.5 million for the third ... for the third quarter of 2007 compared ...
... Calif., Nov. 1 Masimo, the inventor,of Pulse ... announced the completion of CHN,s system-wide implementation of,Masimo ... of superior,Masimo SET performance in other areas of ... pulse oximetry technology to virtually every site --,making ...
... Nov. 1 Talent retention, employee,engagement and retirement ... of,human resources executives in the Best Practices, LLC,s ... in surveys to networking events, roundtable discussions and,information ... that helped them succeed this year. As ...
Cached Medicine News:Health News:Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. 2Health News:Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 2Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 3Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 4Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 5Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 6Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 7Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 8Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 9Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 10Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 11Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 12Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 13Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 14Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 15Health News:Community Health Network of Indianapolis Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 2Health News:Community Health Network of Indianapolis Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 3Health News:Community Health Network of Indianapolis Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 4Health News:Retain Talent and Engage Employees in 2008 2
(Date:8/31/2015)... Mich. , Aug. 31, 2015  Diplomat Pharmacy, Inc. ... has announced that Phil Hagerman , Chairman & CEO, ... upcoming investor conferences. Mr. Hagerman and Mr. ... Healthcare Conference in Boston on Wednesday, ... Hagerman and Mr. Whelan are also scheduled to participate in ...
(Date:8/31/2015)... , Aug. 31, 2015  Qualcomm Incorporated ... subsidiary, Qualcomm Life, Inc., is collaborating ... chronic care management solutions powered by Qualcomm Life,s ... Platform to enable continuous care, informed interventions and ... announced at Qualcomm Life,s annual Connect 2015 ...
(Date:8/31/2015)... , Aug. 31, 2015  Asterias Biotherapeutics, ... on the emerging field of regenerative medicine, today ... at Chicago -based Rush University ... evaluating activity of escalating doses of AST-OPC1 (oligodendrocyte ... and motor complete cervical spinal cord injury (SCI). ...
Breaking Medicine Technology:Diplomat to Participate in Upcoming Investor Conferences 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 3Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 4Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6
... /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: ... medical devices worldwide, announced today that it will attend ... Fuzhou, China between October 31 and November 3, 2011. ... products from its three primary business segments: patient monitoring ...
... SINGAPORE, Oct. 25, 2011 S*BIO Pte Ltd today announced ... its novel JAK2 inhibitor pacritinib (SB1518), in the first half ... the treatment of myelofibrosis (MF). The company is actively exploring ... "Data from Phase 1 and 2 clinical ...
Cached Medicine Technology:Mindray Medical to Exhibit New Products at 66th China International Medical Equipment Fair 2Mindray Medical to Exhibit New Products at 66th China International Medical Equipment Fair 3S*BIO to Initiate Global Phase 3 Clinical Trials of its Novel JAK2 Inhibitor Pacritinib for Treatment of Myelofibrosis (MF) 2
... technology enables a fast, precise patternless edge ... Introducing the TOPCON ALE-X1. The latest advance ... of improved features and functions. High-speed processing, ... and beveled edges, precise three-dimensional frame tracing ...
Inquire...
Inquire...
A professionally designed instrument for obtaining accurate measurements of the corneal curvature. The convenient configuration also facilitates measuring contact lens curvatures....
Medicine Products: